Should Cardiac MRI Be Ordered for Septal Hypertrophy on Echo?
Yes, cardiac MRI should be ordered for septal hypertrophy identified on echocardiography when the echo is inconclusive for diagnosis, when you need to assess for alternative diagnoses (infiltrative/storage diseases), when planning septal reduction therapy, or when sudden cardiac death risk stratification remains uncertain after standard clinical assessment.
Primary Indications for Cardiac MRI (Class I Recommendations)
The 2020 AHA/ACC guidelines provide clear Class I (strongest) recommendations for when cardiac MRI is indicated 1:
1. Inconclusive Echocardiography
- Order cardiac MRI when echo findings are inconclusive for establishing the diagnosis of HCM 1
- Echo can underestimate or overestimate maximal LV wall thickness compared to CMR, which directly impacts sudden cardiac death risk assessment 2
- Apical aneurysms may be missed on echo but are critical for risk stratification 2
2. Differential Diagnosis
- Order cardiac MRI when you suspect alternative diagnoses including:
- Infiltrative diseases (amyloidosis, sarcoidosis)
- Storage diseases (Anderson-Fabry disease, glycogen storage disorders)
- Athlete's heart 1
- CMR can differentiate these conditions through tissue characterization patterns that echo cannot provide 3
3. Sudden Cardiac Death Risk Stratification
- Order cardiac MRI when SCD risk remains uncertain after standard assessment (personal/family history, echo, ambulatory ECG monitoring) 1
- CMR provides critical information:
- Precise maximal LV wall thickness measurement (major SCD risk marker)
- Detection of LV apical aneurysms (high-risk feature)
- Quantification of myocardial fibrosis via late gadolinium enhancement (LGE)
- Accurate ejection fraction assessment 2
- Extensive LGE (≥15% of LV mass) is associated with 2-fold increased SCD risk 2
- Absence of or minimal LGE indicates lower SCD risk 2
4. Planning Septal Reduction Therapy
- Order cardiac MRI when the anatomic mechanism of obstruction is unclear on echo 1
- CMR reliably characterizes LVOT anatomy including:
- Precise distribution of septal hypertrophy
- Mitral valve and subvalvular apparatus abnormalities
- Abnormally positioned papillary muscles
- Anomalous papillary muscle insertion
- Accessory muscle bundles 2
When Echo Alone May Be Sufficient
Echo remains the primary imaging modality and may be adequate when 4:
- Diagnosis is clear and unequivocal
- Image quality is excellent with complete visualization
- No concern for alternative diagnoses
- SCD risk stratification is straightforward based on standard clinical criteria
- No plans for septal reduction therapy
Practical Clinical Algorithm
Order cardiac MRI if ANY of the following apply:
Diagnostic uncertainty:
- Poor echo windows
- Suspected apical hypertrophy (near-field artifacts on echo) 3
- Atypical hypertrophy patterns
- Wall thickness measurements seem discordant with clinical picture
Red flags for alternative diagnoses:
- Age >65 years with new-onset hypertrophy
- Concentric rather than asymmetric hypertrophy
- Biventricular hypertrophy
- Restrictive physiology with mildly reduced EF
- Sparkling/granular myocardial texture on echo
- Thickened interatrial septum
- Small pericardial effusion 3
Risk stratification needs:
- Borderline wall thickness measurements (13-15mm where precise measurement matters)
- Uncertain ICD decision after standard workup
- Family history of sudden cardiac death
- Need to assess extent of fibrosis
Treatment planning:
- Considering septal myectomy or alcohol ablation
- Unclear mechanism of LVOTO on echo
Important Caveats
- Measurement discrepancies: Echo and CMR can differ in wall thickness measurements by 1-3mm, with greater discrepancy at sites distant from the echo transducer 5, 6
- Complementary, not competitive: CMR doesn't replace echo but provides complementary information that echo cannot 4, 7
- Contraindications matter: If CMR is contraindicated (pacemaker/ICD without MRI-conditional device, severe claustrophobia, GFR <30), cardiac CT may be considered as an alternative 1
Repeat CMR Considerations (Class IIb)
Periodic repeat CMR every 3-5 years may be considered for ongoing SCD risk stratification to evaluate 1:
- Changes in LGE extent
- Development of apical aneurysm
- Changes in EF or wall thickness
- This is weaker evidence (Class IIb) and should be individualized based on clinical trajectory
The bottom line: Don't rely solely on echo when septal hypertrophy is identified. Cardiac MRI provides critical diagnostic, prognostic, and therapeutic planning information that frequently changes management, particularly for risk stratification and ruling out phenocopies.